Nanoemulsion Adjuvanted Vaccines Continue to Demonstrate Positive Pre-Clinical Results in Genital Herpes, HIV and Chlamydia
NanoBio Corporation, a biopharmaceutical company focused on developing and commercializing intranasal and intramuscular vaccines, today announced that its intranasal nanoemulsion (NE) adjuvanted chlamydia vaccine has demonstrated efficacy in a traditional mouse challenge model. The study was conducted by leading chlamydia vaccine researchers at the Queensland University of Technology (QUT) in Brisbane, Australia led by Dr. … Continued